2018-08-15

[#DIV28SUPER] Register for our Nov. Substance Use and Addiction Conference in Washington, DC

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] Call for Papers: Experimental and Clinical Psychopharmacology

Special Issue for April 2019 on:

Therapeutic and Abuse-Related Effects of Cannabis and Cannabinoids

 

This special issue will provide an overview of current research on cannabis and cannabinoids with an emphasis on issues related to their legalization for medical and recreational use.  We encourage submission of review articles and original research reports in this area, including the following topics: therapeutic efficacy of cannabis and cannabinoids across different disease conditions; etiology of cannabinoid use disorders; consequences of cannabinoid exposure during pregnancy, adolescence, and adulthood; development of forensic testing for detecting acute cannabis intoxication;  influence of route of cannabinoid administration on therapeutic effects and abuse liability;  variations in THC content across cannabis strains and cannabinoid-enriched products, and implications for use; current federal restrictions on cannabis research; prevalence of synthetic cannabinoids, issues with their regulation, mechanisms of action and consequences of their use; and changes in public perceptions of perceived harm of medicinal and recreational cannabis and cannabinoid use.

 

Researchers in this area may submit review articles or primary research reports to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (http://pha.edmgr.com/), and the cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue on Therapeutic and Abuse-Related Effects of Cannabis and Cannabinoids.  All submissions will undergo our normal peer review. Manuscripts received no later than October 1, 2018 will be considered for inclusion in the special issue. We strongly encourage individuals to contact the guest editors in advance with their ideas and a draft the title and abstract.

 

Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, Ashley Acheson, PhD, awacheson@uams.edu, or William Fantegrossi, wefantegrossi@uams.edu, or the Editor, William Stoops, PhD at william.stoops@uky.edu.



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2018-08-14

[#DIV28SUPER] Postdoc in HIV and Addictions at Duke

Dear APA 28 Division 28 Forum, 

Our lab is looking to hire a full-time postdoctoral fellow. Could you please post the ad pasted below to the Div 28 listserv? 

Many thanks!
Christina

----------------------------------------------------------------
Christina S. Meade, PhD
Associate Professor, Department of Psychiatry & Behavioral Sciences
Duke University School of Medicine

Brightleaf Square
905 W. Main St., Suite 24-E
Durham, NC, 27701
919.613.6549
christina.meade@duke.edu
 
Website: http://sites.duke.edu/harp/ 
Twitter: twitter.com/HARPatDuke   


Position Announcement

Postdoctoral Associate

 The HIV and Addictions Research Program (HARP), directed by Dr. Christina Meade, is seeking a full-time postdoctoral fellow with a strong background in cognitive neuroscience and MRI data analysis. Our team seeks to understand how drug addiction and HIV infection together impact the brain, and in turn affect neurocognitive functioning. With a recently funded R01 to conduct multi-modal data fusion analyses on an existing MRI dataset (resting state fMRI, diffusion tensor imaging, and high-resolution structural scanning), we are seeking a postdoctoral fellow to make significant contributions to data analysis and manuscript writing. The postdoctoral fellow will also be responsible for assisting with data collection and management of ongoing clinical studies that include multi-modal MRI. This position is ideal for individuals interested in pursuing an independent research career in an academic setting, and the fellow will be supported in the pursuit of independent funding (e.g., NRSA fellowship, K Award). The position is located at the Duke University Medical Center in Durham, NC.

 Work Performed

Responsibilities will include MRI data management and analysis; computer programming for managing and processing MRI and related data; manuscript writing; data collection with human subjects, including obtaining informed consent; training other lab members on MRI-related analyses; and administrative tasks, such as MRI protocol renewals. The position entails planning, executing, and troubleshooting analyses with minimal supervision on a daily basis. The opportunity for first-author manuscripts exists, and publication will be encouraged.

 Education & Experience

Doctoral degree with training in neuroimaging (data acquisition, management, and analysis) is required. Interest in HIV and/or drug addiction is ideal. Experience with patient-oriented research is preferred.  

 Key Skills

Successful applicants must be motivated, reliable, and mature, able to multi-task and learn new tasks quickly, and have strong interpersonal, organizational, and communication skills (both verbal and written). The fellow is expected to conduct MRI data processing and analyses independently, including the programming and implementation of automated scripts. Strong programming skills are required. Experience with MRI experimental design and data acquisition is desirable. Ideal software knowledge includes FSL, MATLAB, linus, and statistical packages such as SPSS. The fellow is expected to work both independently and as part of our active research team.

 The proposed start date is fall 2018. Review of applications will begin immediately and will continue until the position is filled. The initial appointment will be for 1 year, with additional funding conditional upon satisfactory performance. Salary is commensurate with NIH guidelines and applicant experience.

 To apply, please send a CV, statement of interest, relevant manuscripts, and names of three references to christina.meade@duke.edu


2018-08-08

[#DIV28SUPER] UVM NIH POSTDOCTORAL RESEARCH FELLOWSHIP POSITION


NIH Postdoctoral Research Fellowship Opportunity

 

The University of Vermont's Center on Behavior and Health announces an NIH postdoctoral research fellowship opportunity in our internationally recognized center of excellence for the study of substance abuse. The fellow will participate in the conduct of an ongoing NIDA/FDA-funded trial on the use of tobacco in vulnerable populations, as well as develop new research opportunities in related areas. The mentoring team has an exceptional track record of helping fellows further their careers as independent investigators.

 

Eligibility: Applicants must have completed their training in psychology, behavior analysis, or a related discipline. Trainees are selected on the basis of scholastic record and commitment to a career in tobacco research. Individuals must be highly motivated, possess initiative and a desire to learn and expand their interests and expertise. Experience with behavioral economics is highly valued. There may be additional application requirements if you are a non-US citizen or non-permanent resident. Appointment:  2-3 yrs.

 

Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.

 

To apply: Send application form (downloaded from VCBH website), a cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Diann Gaalema c/o Ms. Marissa Wells (mwells2@uvm.edu). 

 

About us: The VCBH was established in 2013, sponsored in part by a Centers of Biomedical Research Excellence (COBRE) Award from the National Institute on General Medical Sciences and a Centers of Tobacco Regulatory Science (TCORS) Award from the National Institute on Drug Abuse. The VCBH resides within the College of Medicine at the University of Vermont, with the director and administrative offices being located within the Department of Psychiatry, and participating investigators, collaborators, and advisors across 15 academic departments in the College of Medicine and 7 colleges within UVM and 5 other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels. The focus of the VCBH is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk, and developing effective interventions and policies to promote healthy behavior.

 

For more information:  Contact Ms. Marissa Wells, mwells2@uvm.edu or see our website.

 

Burlington, Vermont is located in the beautiful Lake Champlain region, surrounded by the Green and Adirondack Mountains. It is a great place for families, boasting excellent schools and year-round recreational opportunities. It is home to the University of Vermont and many other colleges that provide an academically stimulating and culturally rich environment. Montreal and Boston are within easy driving distances.


--

Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior and Health
Virginia H. Donaldson Professor of Translational Science
Departments of Psychiatry and Psychological Science
Vice Chair, Department of Psychiatry
University of Vermont
1 South Prospect Street
Burlington, VT  05401-1419

VCBH Administrator: Marissa Wells, MPH
mwells2@uvm.edu
802-656-0079

2018-08-06

[#DIV28SUPER] Important Funding Opportunities you should know about, NIDA Neuroscience Update August 6, 2018

 

I.         PAR-18-789 Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed)

Application due dates: August 21, 2018, March 19, 2019; August 21, 2019, March 19, 2020; August 21, 2020, March 19, 2021, by 5:00 PM local time of applicant organization.

 

II.        PAR-18-226  Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)   Application deadline: October 19, 2018, by 5:00 PM local time of applicant organization

 

III.      PAR-18-084: Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) Standard receipt dates, FOA expires Sept 8, 2019 (not 2018)

 

IV.      PAR-17-242/PAR-17-250 Extracellular Vesicles and Substance Use Disorders (R21) and R01)

Application deadline: November 3, 2018, March 3, 2019, November 3, 2019, March 3, 2020 , by 5:00 PM local time of applicant organization.

 

V.       PAR-18-742 Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)  Application deadline: November 13, 2018 February 11, 2019, July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021, by 5:00 PM local time of applicant organization

 

VI.      Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)

Application deadline: August 20, 2018; December 20, 2018; August 20, 2019; December 20, 2019; August 20, 2020; and December 18, 2020, by 5:00 PM local time of applicant organization.

 

VII.    Call for Presentations by funded NIDA and NIAAA Early Stage and New Investigators to present at the 2018 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention on Friday, November 2, in San Diego, CA, Satellite to Society for Neuroscience Meeting. Please complete the ECIS application form

VIII.    Hold the date for the NIDA Genetics Consortium Meeting, Monday, January 14 through January 15, 2019.  

 

------------------------

 

I.           PAR-18-789 Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed)  Application due dates: August 21, 2018, March 19, 2019; August 21, 2019, March 19, 2020; August 21, 2020, March 19, 2021, by 5:00 PM local time of applicant organization.

 

The goals of this initiative are to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ genetic and genomics strategies. We also encourage applications that take genetic and/or genomics approaches to integrate data, delineate gene networks, and uncover the function of known or newly discovered genetic or epigenetic variants.

Investigators examining the phenotype of knockout mice are discouraged from submitting applications to this FOA. Instead, they should submit applications in response PA-17-155 (R01) PA-17-157 (R21) Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders.”

 

II.     PAR-18-226  Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)   Application deadline: October 19, 2018, by 5:00 PM local time of applicant organization

 

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction.  These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction.  Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply.  The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

III.   PAR-18-084: Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) Standard receipt dates, FOA expires Sept 8, 2019 (not 2018)

 

The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

 

IV.     PAR-17-242/PAR-17-250 Extracellular Vesicles and Substance Use Disorders (R21) and R01)  Application deadline: November 3, 2018, March 3, 2019, November 3, 2019, March 3, 2020 , by 5:00 PM local time of applicant organization.

 

The purpose of this FOA is to encourage research projects that investigate the interplay between EVs and SUDs.  In particular, NIDA is interested in the potential utility of EVs with respect to understanding neuroplastic mechanisms relevant to SUDs or as biomarkers or therapeutics.

 

Proposed projects are expected to meet the following two criteria: 1) the major thrust of the application should involve extracellular vesicles or EV biogenesis machinery; and 2) at least one aim or sub-aim should involve exposure to addictive substances, or analysis of samples from patients with substance use or SUDs. Addictive substances of interest include: nicotine, cocaine, stimulants, opioids, prescription drugs, cannabinoids, or use of multiple substances (including alcohol).  Applications focused solely on alcohol exposure should not apply through this FOA. 

 

V.    PAR-18-742 Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)  Application deadline: November 13, 2018 February 11, 2019, July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021, by 5:00 PM local time of applicant organization

 

The purpose of this initiative is to encourage research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain.  Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response

 

VI     Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)

Application deadline: August 20, 2018; December 20, 2018; August 20, 2019; December 20, 2019; August 20, 2020; and December 18, 2020, by 5:00 PM local time of applicant organization.

 

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking; and/or (2) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research. 

 

 

VII.         Call for Presentations by funded NIDA and NIAAA Early Stage and New Investigators to present at the 2018 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention on Friday, November 2, in San Diego, CA, Satellite to Society for Neuroscience Meeting.

This year’s scientific sessions for the 2018 Mini-Convention will explore: 1) data science – new paradigms for addiction research; 2) effects of early life adversity on substance use disorder-related circuitry; and 3) novel opioid receptor signaling in addiction and pain.

Funded NIDA and NIAAA Early Stage ESI and New Investigators are urge to submit papers for oral presentation at the Early Career Investigator Showcase [ECIS] session of the 2018 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention. Investigators whose papers are selected for presentation at the ECIS will be provided with a travel award to attend the meeting. Individuals selected for ECIS will be chosen for the quality of their research, its impact in the field, and its relevance to the mission of NIDA or NIAAA. Preference will be given to presentations that address a scientific session of the 2018 Mini-Convention. 

Please complete the ECIS application form contained in this hyperlink.   Applications are due by 17 August 2018. Please send your application by email to: Roger Sorensen, NIDA [rsorense@mail.nih.gov ] or John Matochik, NIAAA [jmatochi@mail.nih.gov ].

VIII.         Hold the date for the NIDA Genetics Consortium Meeting, Monday, January 14 through January 15, 2019

 

The NIDA Genetics Consortium meeting is where the latest information and data about the of science of genetics and epigenetics of substance abuse is presented.  A call for posters presentation will occur in late September -early October, 2018.  For more information contact

Jonathan D. Pollock,Ph.D. (jpollock@mail.nih.gov, 301-435-1309) or Amy Lossie, Ph.D. (amy.lossie@nih.gov 301-827-6069)

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

2018-08-02

[#DIV28SUPER] Post-Doctoral Fellowship at the University of Kentucky

Post-Doctoral Fellowship

** Available Immediately ***

The Laboratory of Human Behavioral Pharmacology at the University of Kentucky College of Medicine is seeking applicants for a post-doctoral fellowship. This is a two-year fellowship, with an optional third year, funded by the National Institute on Drug Abuse (NIDA) that is designed to train researchers in behavioral pharmacology and clinical trials in the treatment of drug use disorders. The fellowship also provides ample opportunity for professional development, including grant writing and enhancing presentation and publication skills. Applicants should be highly motivated, have recently obtained a doctorate in psychology, pharmacology or a related discipline and must be a U.S. citizen or permanent resident. The fellowship includes salary, tuition (if applicable) and expenses for travel to conferences.  

To Apply: Submit a cover letter stating your research interests along with CV and 3 letters of reference to: william.stoops@uky.edu. The application review begins immediately and will continue until the position is filled. This is a full-time position that is available now.  

For further inquiries, contact:

-Dr. Joshua A. Lile

Associate Professor, Department of Behavioral Science, University of Kentucky College of Medicine

jalile2@uky.edu

-Dr. Craig R. Rush

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

Crush2@email.uky.edu

-Dr. William W. Stoops

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

William.stoops@uky.edu



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2018-08-01

[#DIV28SUPER] NIH PREDOCTORAL RESEARCH FELLOWSHIP OPPORTUNTIES

NIH Predoctoral Research Fellowship Opportunities

The University of Vermont's Center on Behavior and Health announces NIH predoctoral research fellowship opportunities in our internationally recognized center of excellence for the study of substance abuse. The fellows will participate in studies using behavioral economics and behavioral pharmacology to investigate relationships between personal behaviors and risk for chronic disease, specifically focusing on developing effective behavior change interventions. The mentoring team has an exceptional track record of helping fellows further their careers as independent investigators.

 

Eligibility: Applicants must have completed their undergraduate degree in psychology, behavior analysis, or a related discipline. Trainees are selected on the basis of scholastic record and commitment to a career in behavior and health research. Individuals must be highly motivated, possess initiative and a desire to learn and expand their interests and expertise. Experience with behavioral economics is highly valued. Please note, there may be special application requirements if you are a non-US citizen or non-permanent resident.  Appointment: 5 years

 

Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.

 

To apply:  Applicants must apply through the UVM Department of Psychological Science (see https://www.uvm.edu/cas/psychology/application-process for complete instructions).

  

About us: The VCBH was established in 2013, sponsored in part by a Centers of Biomedical Research Excellence (COBRE) Award from the National Institute on General Medical Sciences and a Centers of Tobacco Regulatory Science (TCORS) Award from the National Institute on Drug Abuse. The VCBH resides within the College of Medicine at the University of Vermont, with the director and administrative offices being located within the Department of Psychiatry, and participating investigators, collaborators, and advisors across 15 academic departments in the College of Medicine and 7 colleges within UVM and 5 other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels. The focus of the VCBH is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk, and developing effective interventions and policies to promote healthy behavior.

 

For more information:  Contact Ms. Marissa Wells, mwells2@uvm.edu or see our website.

Burlington, Vermont is located in the beautiful Lake Champlain region, surrounded by the Green and Adirondack Mountains. It is a great place for families, boasting excellent schools and year-round recreational opportunities. It is home to the University of Vermont and many other colleges that provide an academically stimulating and culturally rich environment. Montreal and Boston are within easy driving distances.


--

Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior and Health
Virginia H. Donaldson Professor of Translational Science
Departments of Psychiatry and Psychological Science
Vice Chair, Department of Psychiatry
University of Vermont
1 South Prospect Street
Burlington, VT  05401-1419

VCBH Administrator: Marissa Wells, MPH
mwells2@uvm.edu
802-656-0079